HT
EGRX

Headlands Technologies’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Headlands Technologies’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,674
Closed -$6.24K – 1678
2024
Q3 		$6.24K Buy
+1,674
New +$7.99K ﹤0.01% 1052
2024
Q2 		– Sell
-6,641
Closed -$34.8K – 1701
2024
Q1 		$34.8K Buy
6,641
+2,861
+76% +$15.7K 0.01% 795
2023
Q4 		$19.8K Buy
3,780
+1,454
+63% +$14.4K 0.01% 668
2023
Q3 		$36.7K Buy
2,326
+1,686
+263% +$30.3K 0.02% 493
2023
Q2 		$12.4K Buy
+640
New +$15.2K ﹤0.01% 608

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Headlands Technologies's EGRX Position: Q4 2024 in Review

Headlands Technologies sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 1,674 shares — an estimated $6.24K sold.

Headlands Technologies first reported a position in EGRX in Q2 2023 and held it in 5 quarters. The position peaked at $36.7K in Q3 2023. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Headlands Technologies reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Headlands Technologies sold 1,674 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $6.24K.
  • Headlands Technologies first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2023 and held it in 5 quarters.
  • Headlands Technologies's Eagle Pharmaceuticals, Inc. position peaked at $36.7K in Q3 2023.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Headlands Technologies's 13F filing for Q4 2024, filed 12 Feb 2025.